The company said the layoffs and cost reductions are part of a restructuring plan that will adjust and optimize its supply chain network.
“We do expect some employee attrition and limited headcount reductions to result from these restructuring activities. We are committed to providing these individuals our support to help with their transition,” Boston Scientific stated.
The company said that while job cuts will take place, its headcount will remain relatively stable because it plans to create jobs in growth areas.
The restructuring is expected to be complete by the end of 2021.
More articles on supply chain:
Samsung Galaxy wants to help patients manage insulin therapy
Red Cross issues call for blood donations ahead of holidays
FDA’s cybersecurity policies for postmarket medical devices are ‘insufficient,’ OIG finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.